★ Analysts see FY2026 revenue reaching $4.6B — +6.6% growth in a single year.
What Moves the Stock
01Consumable revenue growth and instrument utilization rates (pull-through per instrument), indicating installed base productivity and end-market demand strength
02NovaSeq X adoption trajectory and competitive positioning against emerging long-read sequencing technologies (PacBio, Oxford Nanopore)
03Clinical diagnostics revenue growth, particularly multi-cancer early detection tests and liquid biopsy adoption rates in oncology
05China revenue exposure (historically 15-20% of sales) and geopolitical risks affecting instrument exports and consumable demand
06Consumables (reagents, flow cells, library prep kits): approximately 65-70% of revenue, recurring high-margin sales tied to installed base utilization
07Sequencing instruments (NovaSeq X, NextSeq 2000): approximately 20-25% of revenue, capital equipment sales with 3-5 year replacement cycles
08Services and other (maintenance contracts, array products): approximately 10-15% of revenue
growth - Illumina attracts investors seeking exposure to the structural growth of genomics applications across precision medicine…
Rising interest rates negatively impact Illumina through two channels: (1) biotech/pharma customers face higher capital costs…
Watch on earnings: NovaSeq X instrument placements per quarter and consumable pull-through rates (revenue per instrument annually), Clinical diagnostics revenue growth rate and oncology testing partnership announcements (GRAIL separation impact), China revenue trends and geographic diversification progress amid geopolitical tensions.
One Sentence Summary:
Illumina: the story is balanced — consumable revenue growth and instrument utilization rates (pull-through per instrument).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
